Corona Remedies IPO Allotment: How To Check Status Online? Direct Links To BSE, NSE, Bigshare; Latest GMP Here

Corona Remedies IPO Allotment: The allotment status of Corona Remedies' Rs 655.37 crore public offer is going to be out on December 11. Investors can check their application status on BSE, NSE, and Bigshare Services. The current grey market premium (GMP) signalled at more than 27% premium listing.

Corona Remedies IPO Allotment:

The key information required for checking Corona's IPO allotment status are application number, PAN card, demat account, or IFSC code. The online method to check is BSE, NSE and Bigshare Services.

Corona Remedies IPO Allotment Bigshare:

Step 1: Visit the main page of Bigshare IPO allotment status. Click below.

https://www.bigshareonline.com/ipo_allotment.html

Step 2: Select either of the servers mentioned on the page.

Step 3: You will have to select company name. Then select between the options like Application no, Beneficiary ID or PAN number.

Step 4: After feeding either of the information, enter captcha code correctly. Then select on 'SEARCH.

Corona Remedies IPO Allotment BSE:

Step 1: Visit BSE Status of Issue Application page. Get the direct link below:

https://www.bseindia.com/investors/appli_check.aspx

Step 2: Select issue type 'Equity'.

Step 3: Select issue name 'Corona Remedies'

Step 4: Bidders will have to enter either application number or PAN card before clicking on SEARCH option.

You will be directed to a new page where the status of your application will be available.

Corona Remedies IPO Allotment NSE:

Step 1: Visit the main IPO allotment page of NSE. Direct below!

https://www.nseindia.com/invest/check-trades-bids-verify-ipo-bids

Step 2: For Corona, you have to select 'Equity & SME IPO Bid Details' option.

Step 3: Select the symbol 'CORONA'

Step 4: Enter both PAN card and application number. Lastly, click on SUBMIT.

Corona Remedies IPO GMP Today:

Corona Remedies IPO last GMP is Rs 291, last updated Dec 11th 2025 11:58 AM. With the price band of 1062.00, Corona Remedies IPO's estimated listing price is Rs 1353 (cap price + December 11th GMP).The expected percentage gain/loss per share is 27.40%, as per Investor Grain.

Corona Remedies IPO Listing Date:

After the allotment status, the company will either credit shares to eligible shareholders or issue refund on December 12. However, the listing will be done on December 15, due to weekend holiday on December 13th and December 14th.

Corona Remedies opened its IPO from December 8th to December 10th, at a price band of Rs 1,008 per share to Rs 1,062 per share. On the final day, Corona recorded a whopping 137.04 times oversubscription with strong demand from qualified institutional buyers and non-institutional investors whose portion oversubscribed by 278.52 times and 208.88 times respectively. The retail portion and employees reserved category oversubscribed by 28.73 times and 14.72 times respectively.

In its IPO note, Geojit report said, with a strong distribution network, successful acquisitions and in-licensing, resilient financial performance, lean balance sheet and continued focus on R&D and innovation, the company is well-positioned for long-term growth.

Further, Choice Broking research analyst Rajnath Yadav in a report said the company has demonstrated consistent revenue and profit growth, supported by healthy margins. Around 70% of its revenue is derived from chronic therapies, which are typically high-margin and exhibit strong prescription stickiness. CRL primarily focuses on chronic segments such as women's healthcare, cardiology, and diabetes, offering long-term growth visibility. Also, CRL's IPM ranking has improved from 37th to 29th, reflecting rising scale and competitiveness.

Between FY23-FY25, CRL demonstrated strong financial resilience with Revenue, EBITDA, and PAT growing at CAGRs of 16.3%, 36.9%, and 32.6%, driven by consistent topline growth, improved efficiency, and stronger profitability.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.